|
1
|
Li S, Young KH and Medeiros LJ: Diffuse
large B-cell lymphoma. Pathology. 50:74–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roschewski M, Staudt LM and Wilson WH:
Diffuse large B-cell lymphoma-treatment approaches in the molecular
era. Nat Rev Clin Oncol. 11:12–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coiffier B and Sarkozy C: Diffuse large
B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc
Hematol Educ Program. 2016:366–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao HX, Nuerlan A, Abulajiang G, Cui WL,
Xue J, Sang W, Li SJ, Niu J, Ma ZP, Zhang W and Li XX: Quantitative
proteomics analysis of differentially expressed proteins in
activated B-cell-like diffuse large B-cell lymphoma using
quantitative proteomics. Pathol Res Pract. 215:1525282019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao HX, Li SJ, Niu J, Ma ZP, Nuerlan A,
Xue J, Wang MB, Cui WL, Abulajiang G, Sang W, et al: TCL1 as a hub
protein associated with the PI3K/AKT signaling pathway in diffuse
large B-cell lymphoma based on proteomics methods. Pathol Res
Pract. 216:1527992020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Z, Wang Y, Shu S, Cai J, Tang C and
Dong Z: Non-coding RNAs in kidney injury and repair. Am J Physiol
Cell Physiol. 317:C177–C188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baronti L, Guzzetti I, Ebrahimi P, Friebe
Sandoz S, Steiner E, Schlagnitweit J, Fromm B, Silva L, Fontana C,
Chen AA and Petzold K: Base-pair conformational switch modulates
miR-34a targeting of Sirt1 mRNA. Nature. 583:139–144. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM,
et al: WHO classification of tumours of haematopoetic and lymphoid
tissues. 4th edition. IARC Press; Lyon: 2017
|
|
11
|
Felix TF, Lopez Lapa RM, de Carvalho M,
Bertoni N, Tokar T, Oliveira RA, M Rodrigues MA, Hasimoto CN,
Oliveira WK, Pelafsky L, et al: MicroRNA modulated networks of
adaptive and innate immune response in pancreatic ductal
adenocarcinoma. PLoS One. 14:e02174212019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xue J, Gao HX, Sang W, Cui WL, Liu M, Zhao
Y, Wang MB, Wang Q and Zhang W: Identification of core
differentially methylated genes in glioma. Oncol Lett.
18:6033–6045. 2019.PubMed/NCBI
|
|
13
|
Hu S, Zheng Q, Wu H, Wang C, Liu T and
Zhou W: miR-532 promoted gastric cancer migration and invasion by
targeting NKD1. Life Sci. 177:15–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kakurina GV, Kolegova ES, Shashova EE,
Cheremisina OV, Choynzonov EL and Kondakova IV: Relationship
between the mRNA expression levels of calpains 1/2 and proteins
involved in cytoskeleton remodeling. Acta Naturae. 12:110–113.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Due H, Brøndum RF, Young KH, Bøgsted M and
Dybkær K: MicroRNAs associated to single drug components of R-CHOP
identifies diffuse large B-cell lymphoma patients with poor outcome
and adds prognostic value to the international prognostic index.
BMC Cancer. 20:2372020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li L, Lei Q, Zhang S, Kong L and Qin B:
Screening and identification of key biomarkers in hepatocellular
carcinoma: Evidence from bioinformatic analysis. Oncol Rep.
38:2607–2618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khordadmehr M, Shahbazi R, Sadreddini S
and Baradaran B: miR-193: A new weapon against cancer. J Cell
Physiol. 234:16861–16872. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Musilova K and Mraz M: MicroRNAs in B-cell
lymphomas: How a complex biology gets more complex. Leukemia.
29:1004–1017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beheshti A, Stevenson K, Vanderburg C,
Ravi D, McDonald JT, Christie AL, Shigemori K, Jester H, Weinstock
DM and Evens AM: Identification of circulating serum multi-MicroRNA
signatures in human DLBCL models. Sci Rep. 9:171612019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ting CY, Liew SM, Price A, Gan GG, Bee-Lan
Ong D, Tan SY and Bee PC: Clinical significance of aberrant
microRNAs expression in predicting disease relapse/refractoriness
to treatment in diffuse large B-cell lymphoma: A meta-analysis.
Crit Rev Oncol Hematol. 144:1028182019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoon S, Nguyen HCT, Jo W, Kim J, Chi SM,
Park J, Kim SY and Nam D: Biclustering analysis of transcriptome
big data identifies condition-specific microRNA targets. Nucleic
Acids Res. 47:e532019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shim H, Nam J and Kim SW: NF-κB p65
represses microRNA-124 transcription in diffuse large B-cell
lymphoma. Genes Genomics. 42:543–551. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao CC, Jiao Y, Zhang YY, Ning J, Zhang
YR, Xu J, Wei W and Kang-Sheng G: Lnc SMAD5-AS1 as ceRNA inhibit
proliferation of diffuse large B cell lymphoma via Wnt/β-catenin
pathway by sponging miR-135b-5p to elevate expression of APC. Cell
Death Dis. 10:2522019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang Y, Yang J, Wang Y, Tang Z, Liu S and
Tang Y: MiR-19b-3p facilitates the proliferation and
epithelial-mesenchymal transition, and inhibits the apoptosis of
intrahepatic cholangiocarcinoma by suppressing coiled-coil domain
containing 6. Arch Biochem Biophys. 686:1083672020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park EJ, Jung HJ, Choi HJ, Jang HJ, Park
HJ, Nejsum LN and Kwon TH: Exosomes co-expressing AQP5-targeting
miRNAs and IL-4 receptor-binding peptide inhibit the migration of
human breast cancer cells. FASEB J. 34:3379–3398. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marcuello M, Duran-Sanchon S, Moreno L,
Lozano JJ, Bujanda L, Castells A and Gironella M: Analysis of A
6-mirna signature in serum from colorectal cancer screening
participants as non-invasive biomarkers for advanced adenoma and
colorectal cancer detection. Cancers (Basel). 11:15422019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang SS, Huang ZG, Wu HY, He RQ, Yang LH,
Feng ZB, Dang YW, Lu HP, Fang YY and Chen G: Downregulation of
miR-193a-3p is involved in the pathogenesis of hepatocellular
carcinoma by targeting CCND1. PeerJ. 8:e84092020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin M, Zhang Z, Gao M, Yu H, Sheng H and
Huang J: MicroRNA-193a-3p suppresses the colorectal cancer cell
proliferation and progression through downregulating the PLAU
expression. Cancer Manag Res. 11:5353–5363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen ZM, Yu Q, Chen G, Tang RX, Luo DZ,
Dang YW and Wei DM: MiR-193a-3p inhibits pancreatic ductal
adenocarcinoma cell proliferation by targeting CCND1. Cancer Manag
Res. 11:4825–4837. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li LM, Luo FJ and Song X: MicroRNA-370-3p
inhibits cell proliferation and induces chronic myelogenous
leukaemia cell apoptosis by suppressing PDLIM1/Wnt/β-catenin
signaling. Neoplasma. 67:509–518. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nadaradjane A, Briand J, Bougras-Cartron
G, Disdero V, Vallette FM, Frenel JS and Cartron PF: miR-370-3p is
a therapeutic tool in anti-glioblastoma therapy but is not an
intratumoral or cell-free circulating biomarker. Mol Ther Nucleic
Acids. 13:642–650. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leivonen SK, Icay K, Jäntti K, Siren I,
Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ,
d'Amore F, et al: MicroRNAs regulate key cell survival pathways and
mediate chemosensitivity during progression of diffuse large B-cell
lymphoma. Blood Cancer J. 7:6542017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Zhang X, Yao H, Le Y, Zhou W, Li
J, Lu L, Chen M and Li X: MiR-490-5p functions as tumor suppressor
in childhood neuroblastoma by targeting MYEOV. Hum Cell.
33:261–271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiang M, Yuan W, Zhang W and Huang J:
Expression of miR-490-5p, miR-148a-3p and miR-608 in bladder cancer
and their effects on the biological characteristics of bladder
cancer cells. Oncol Lett. 17:4437–4442. 2019.PubMed/NCBI
|
|
37
|
Valera VA, Parra-Medina R, Walter BA,
Pinto P and Merino MJ: microRNA expression profiling in young
prostate cancer patients. J Cancer. 11:4106–4114. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pan XM, He XY, Yang YL, Jia WJ, Yang ZQ,
Yan D and Ma JX: MiR-630 inhibits papillary thyroid carcinoma cell
growth, metastasis, and epithelial-mesenchymal transition by
suppressing JAK2/STAT3 signaling pathway. Eur Rev Med Pharmacol
Sci. 23:2453–2460. 2019.PubMed/NCBI
|
